Previous 10 |
– Shawn Cline Tomasello and Stephen T. Wills bring extensive experience in building successful commercial-stage life sciences companies – Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced the nominations of Shawn Cline...
Gamida ( GMDA ) is a small, pivotal stage Israeli company developing Nicotinamide-enhanced cell therapies targeting a number of cancers. The clinical proposition is interesting: The company is using its technology to improve the prospects of hematopoietic stem cell transfer or HSCT, which is c...
Gamida Cell (NASDAQ: GMDA ): FY GAAP EPS of -$10.53. More news on: Gamida Cell, Earnings news and commentary, Healthcare stocks news, Read more ...
– Successfully Completed IPO Raising $53.2 Million in Gross Proceeds – – Patient Enrollment in Phase 3 Study of NiCord ® on Track for Completion in Second Half of 2019; Topline Results Expected in First Half of 2020 – – Recently Present...
– Data support ongoing Phase 3 study of NiCord in patients with hematologic malignancies – Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that translational data from the completed Phase 1/2 clinical study of NiCord...
– NAM-NK therapy clinically active and generally well tolerated, with multiple complete responses observed – – Data in severe aplastic anemia support potential of NiCord to treat non-malignant bone marrow failure disorders – – Gamida Cell to host...
Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced an agreement with Editas Medicine, Inc., a leading genome editing company, to evaluate the potential use of Editas Medicine’s CRISPR technology to edit NAM-NK cells, which are natura...
Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that it will host a conference call and webcast on Thursday, February 21, 2019, at 8:00 a.m. ET to review the data from its NAM-NK and NiCord ® programs being presented at the 2019 Tr...
Shares of small Israeli biotech firm Gamida Cell ( GMDA ) have performed admirably out of the gate, rising over 60% so far since its October IPO . One telling sign that this one could do well was the fact that insiders (Novartis and Cial Biotechnology) chose to purchase $37.5 million out of...
News, Short Squeeze, Breakout and More Instantly...
Gamida Cell Ltd. Company Name:
GMDA Stock Symbol:
NASDAQ Market:
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney d...
2024-04-03 06:21:00 ET How to Analyze Different Penny Stocks Sectors to Make Money Investing in penny stocks offers an accessible entry point for individuals aiming to participate in the stock market with a lower initial investment. Analyzing different sectors within the realm of penn...
A look at the top 10 most actives in the United States Trio Petroleum Corp. (TPET) rose 43.8% to $0.1485 on volume of 202,621,744 shares Nikola Corporation (NKLA) fell 5.5% to $0.9736 on volume of 187,304,976 shares C3is Inc. (CISS) rose 13.3% to $0.0409 on volume of 136,767,990 shares ...